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Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No estab-
lished treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the
case of an 81-year-old woman with idiopathic pulmonary ﬁbrosis (IPF), who was admitted to our hos-
pital due to aggravation of dyspnea and decreased oxygen saturation, as well as onset of orthopnea and
rapidly progressing edema. The transthoracic echocardiography and right heart catheterization showed
the mean pulmonary artery pressure was 39 mmHg and the mean pulmonary capillary wedge pressure
was 9 mmHg. After various examinations, the diagnoses of pulmonary hypertension (PH) due to IPF and
of congestive heart failure secondary to PH were established. Diuretic therapy was started, but the pa-
tient's condition showed poor improvement. Subsequent initiation of oral bosentan therapy led to
improvement in symptoms and ﬁndings. At the follow-up assessment one year later her pulmonary
function showed no signiﬁcant changes and no apparent worsening of arterial blood gases, with evident
improvement of PH, WHO functional class, maximum exercise tolerance on treadmill exercise testing,
right heart catheterization, and transthoracic echocardiography.
This report describes a case of successful treatment with bosentan for severe pulmonary hypertension
in a patient with idiopathic pulmonary ﬁbrosis. We also present a review of the literature on treatment of
pulmonary hypertension in patients with chronic lung disease. Bosentan appears to be efﬁcacious in
some patients with pulmonary hypertension secondary to idiopathic interstitial pneumonitis.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The prevalence of pulmonary hypertension (PH) complicating
the course of patients with idiopathic pulmonary ﬁbrosis (IPF) has
been reported to be 32%e85% [1]. According to the Dana Point 2008
classiﬁcation of PH, this type of PH falls under group 3 (i.e.,sure; PH, pulmonary hyper-
hiba-Hokusoh Hospital, Res-
70-1694, Japan. Tel.: þ81 476
Ltd. This is an open access article u“Pulmonary hypertension secondary to lung diseases and/or hyp-
oxemia”), and it is a determinant of the prognosis of patients with
interstitial lung disease. No established treatment guideline has
been available to treat this condition despite discussions at the ﬁfth
World Symposium of Pulmonary Hypertension [2]. We present a
case of remarkable improvement of PH in a patient with idiopathic
pulmonary ﬁbrosis (IPF) after treatment with bosentan, an endo-
thelin antagonist.Case report
The patient was an 81-year-old woman. Around June 2012 she
noticed difﬁcult breathing while walking; then as the symptomnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the same year, bronchoscopy together with bronchoalveolar lavage
(BAL) and transbronchial lung biopsy (TBLB) were performed. The
dominant cells in BAL ﬂuid were monocytes, and TBLB demon-
strated mild lymphocyte inﬁltration and ﬁbroblast hyperplasia.
Respiratory function tests showed restrictive lung disorder with a
percentage vital capacity (%VC) of 63.0%, forced vital capacity (FVC)
of 1.05 L, percentage forced vital capacity (%FVC) of 55.5%, forced
expiratory volume in one second (FEV1) of 1.05 L, percentage of
predicted forced expiratory volume in one second (FEV1%) of
107.1%, and percentage of forced expiratory volume in one second
(Gaensler's FEV1%) of 100.0%. Computed tomography (CT) showed
honeycombing along with traction bronchiectasis in the subpleuralFig. 1. Chest roentgenogram and computed tomography (a). Chest roentgenogram and comp
the subpleural and basal areas of both lungs were detected. (b). Chest roentgenogram and co
the ﬁndings did not show marked progression of IPF, while congestion was prominent witand basal areas of both lungs (Fig. 1a). Findings of physical exami-
nation and blood tests showed no evidence of collagen-vascular
disease or any other condition apart from idiopathic pulmonary
ﬁbrosis. Thus, based on clinical ﬁndings, the patient was diagnosed
idiopathic pulmonary ﬁbrosis (IPF). In addition, the transthoracic
echocardiography showed a tricuspid regurgitation (TR) pressure
gradient of 31.7 mmHg and a pulmonic regurgitation (PR) pressure
gradient of 6.2 mmHg.
The patient was started on oral pirfenidone in February 2013,
but this was discontinued in October 2013 because of difﬁculty
taking oral medication. As for imaging examinations, in August
2013 these ruled out progression of IPF, but the patient showed
aggravation of dyspnea and decreased oxygen saturation, as well asuted tomography at the initial visit Honeycombing along with traction bronchiectasis in
mputed tomography at exacerbation of pulmonary hypertension Compared with Fig. 1a,
h an increased cardiothoracic ratio.
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echocardiography demonstrated ﬁndings consistent with conges-
tive heart failure secondary to pulmonary hypertension (PH), and
thus the patient was started on diuretic therapy. However, her
condition showed little improvement and the patient was thus
hospitalized for detailed examination and treatment in October
2013. Findings of physical examination upon admission included
body temperature 36.9 C, blood pressure 94/52 mmHg, regular
heart rate at 95 beats per minute, respiratory rate 25 breaths per
minute, oxygen saturation 80% (on oxygen 3 L/min by nasal can-
nula), engorged jugular veins on inspection, and bilateral crepita-
tions on auscultation.
Exacerbation of IPF was unlikely because the only signiﬁcant
ﬁnding from imaging examination and blood tests was elevated KL-
6 that was attributed to inﬂuence of diuretic therapy given since
before her admission and inﬂuence of congestion (Table 1 and
Fig. 1b). In addition, after admission, transthoracic echocardiogra-
phy and right heart catheterization were performed. The trans-
thoracic echocardiographic ﬁnding suggested severe PH and a
congestive condition (TR pressure gradient was 86.6 mmHg and PR
pressure gradient was 16.1 mmHg total ejection isovolumetric (Tei)
index was 0.44 and tricuspid annular plane systolic excursion
(TAPSE) was 1.13 cm). (Fig. 2a).
Right heart catheterization showed systolic and diastolic pul-
monary artery pressure (PAP) of 54 and 24 mmHg, respectively
(mean PAP was 39 mmHg) and a systolic and diastolic pulmonary
capillary wedge pressure (PCWP) of 16 and 0 mmHg, respectivelyTable 1
Blood data at the initial visit and admission.
At the initial visit At admission
in Oct. 2013
White blood cells (mm3) 7180 11,650
Red blood cells (  106/ml) 4.81 4.28
Hemoglobin (g/dl) 14.4 13.3
Hematocrit (%) 45.0 40.8
Platelets (  104/mm3) 25.5 24.2
AST (U/l) 23 38
ALT (U/l) 12 23
LDH (U/l) 225 260
ALP (IU/l) 152 232
g-GTP (U/l) 14 29
CPK (IU/l) 48 57
T-Bil (mg/dl) 0.5 0.4
BUN mg/dl 13.8 35.5
Cre (mg/dl) 0.66 0.68
Na (mEq/L) 138 143
K (mEq/L) 4.4 4.5
Cl (mEq/L) 105 109
Total Protein (g/dl) 7.0 6.7
Albumin (g/dl) 3.6 3.4
C-Reactive Protein (mg/dl) <0.05 0.90
BNP (pg/ml) 27.7 1671.82
KL-6 (U/ml) 1848 2435
SP-D (ng/ml) 305.8 420.2
ANA (EIA) 15.7 11.4
MMP-3 (ng/ml) 40.7 90.2
Anti-CCP Ab (U/ml) 1.0 1.0
Anti-DNA Ab (RIA) 9.2 14.9
Anti-RNP Ab ()EIA 5.8 <5.0
Anti-Sm Ab (EIA) <5.0 <5.0
Anti-SS-A Ab (EIA) <5.0 <5.0
Anti-SS-B Ab (EIA) <5.0 <5.0
Anti-Scl70 Ab (EIA) <5.0 <5.0
Anti-Jo-1 Ab (EIA) <5.0 <5.0
Anti-cardiolipin Ab (U/ml) 1 1
Anti-centromere Ab <5.0 <5.0
MPO-ANCA(U/ml) <1.3 <1.3
PR3-ANCA(U/ml) 2.3 <1.3(mean PCWP was 9 mmHg) (Table 2). After various examinations
including lung perfusion scintigraphy that ruled out other diseases
causative of PH, the diagnosis of PH due to IPF was established.
Since treatments such as diuretic therapy and oxygen therapy do
not improve circulatory failure associated with PH, on Day 12 of
hospitalization the patient was started on oral bosentan at a dose of
125 mg/day, leading to rapid improvement of circulatory failure
associated with PH. The dose of bosentanwas increased to 250 mg/
day from hospital Day 25 onward. After improvement of symptoms
and ﬁndings, the patient was discharged from the hospital on long-
term oxygen therapy (using Oxymizer®; dose of oxygen was 3 L/
min at rest and 6 L/min on exertion) (Table 2). At the follow-up
assessment one year later her pulmonary function showed no
signiﬁcant changes and no apparent worsening of arterial blood
gases, with evident improvement of PH, WHO functional class,
maximum exercise tolerance on treadmill exercise testing, right
heart catheterization, and transthoracic echocardiography (Table 2
and Fig. 2b).
Discussion
The prevalence of pulmonary hypertension (PH) complicating
the course of patients with idiopathic pulmonary ﬁbrosis (IPF) has
been reported to vary between 32% and 85%. According to the Dana
Point 2008 classiﬁcation of PH, this type of PH falls under group 3
[3,4]. The pathologic condition has been said to consist of (1) pul-
monary artery vasoconstriction associated with chronic hypox-
emia; (2) structural damage with decreased vascular bed; and (3)
progression of pulmonary vascular lesions due to inﬂammatory
cytokines and other mediators. No established treatment exists for
PH due to lung disease [1,2]. The mainstay of treatment is oxygen
therapy in addition to basal treatment of the primary disease, but it
is unclear if this approach has beneﬁcial effects on the outcome.
Patients typically receive symptomatic treatment with diuretics,
digitalis, and anticoagulants as required. Vasodilators have not
been documented to be efﬁcacious; rather, they may lead to
decreased systemic blood pressure, aggravation of ventilation
perfusion ratio inequality, and worsening of hypoxemia [4]. In this
case, elevation of KL-6was the only ﬁnding that could be suggestive
of exacerbation of IPF, but the elevated KL-6 upon admission was
attributed to congestive heart failure on the basis of absence of
elevation in surfactant protein D (SP-D) or other parameters sug-
gestive of exacerbation of IPF along with the elevated KL-6.
Bosentan was effective for PH associated with the underlying
lung disease, and did not cause any adverse effects such as wors-
ening of the patient respiratory condition. Diuretic therapy failed to
improve congestive heart failure due to PH, but the add-on use of
bosentan improved pulmonary circulation leading to improvement
of systemic hemodynamics. This indicated that bosentan not only
improved congestive heart failure but also directly improved PH. A
published study on ambrisentan, which is another endothelin
antagonist with afﬁnity for the endothelin A receptor, showed that
ambrisentan was associated with IPF disease progression and
signiﬁcantly increased the number of hospitalizations due to res-
piratory problems (i.e., acute exacerbation of IPF or aggravated
respiratory condition) [4]. On the other hand, a study of bosentan, a
non-selective endothelin receptor antagonist, reported that
bosentan did not improve activities of daily living or slowed pro-
gression of symptoms or disease condition in patients with IPF, but
when compared with placebo, bosentan did not worsen IPF, unlike
the endothelin antagonist ambrisentan [5]. While treatment of PH
associated with lung disease remains controversial in many ways,
the present case indicates that bosentan can be efﬁcacious in some
patients with PH associated with idiopathic interstitial pneumo-
nitis, although it cannot be completely ruled out that our patient
Fig. 2. Images from transthoracic echocardiography. (a). Transthoracic echocardiography after admission in Oct. 2013 Upper panels: The right ventricle was enlarged and the
interventricular septum was straightened or bowed into the left ventricle. Middle panels: Severe tricuspid regurgitation (TR) was detected. TR pressure gradient was 86.6 mmHg
Lower panel: Mild pulmonary regurgitation (PR) was detected. PR pressure gradient was 16.1 mmHg Total ejection isovolumetric (Tei) index was 0.44 and tricuspid annular plane
systolic excursion (TAPSE) was 1.13 cm (b). Transthoracic echocardiography at 1 year from start of bosentan therapy Upper panels: Findings improved compared with Fig. 2a. Middle
panels: Severe TR was noted. TR pressure gradient was 48.2 mmHg Lower panel: Mild PR was noted. PR pressure gradient was too small to measure. Tei index was 0.40 and tricuspid
annular plane systolic excursion (TAPSE) was 1.6 cm.
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Table 2
Clinical course.
At the start of bosentan At 1 year of therapy
WHO functional class IV III
Treadmill exercise test 1METs 1.7METs
BNP 1671.82 pg/ml 24.10 pg/ml
Right cardiac catheterization
PAP: Systolic/Diastolic (mean) 54/24 (39) mmHg 48/14 (27) mmHg
PCWP: Systolic/Diastolic (mean) 16/1 (9) mmHg 15/2 (7) mmHg
CO (L/min) 3.2 3.4
PVR (dyne-sec/cm5) 750.0 470.59
KL-6 2435 U/ml 1085 U/ml
SP-D 420.2 U/ml 363.9 U/ml
Arterial blood gases(on oxygen 3 L/min by Oxymizer)
pH 7.409 7.344
PO2 56.6 mmHg 91.5 mmHg
PCO2 50.5 mmHg 48.5 mmHg
Pulmonary function tests (at discharge)
FVC(%) 0.91 L (50.6%) 0.89 L (50.0%)
FEV1(%) 0.91 L (113.8%) 0.89 L (115.8%)
FEV1%(G) 100% 100%
METS: metabolic equivalents, PAP: Pulmonary artery pressure, PCWP: pulmonary
capillary wedge pressure PO2: arterial O2 pressure, PCO2: arterial CO2 pressure, FVC:
forced vital capacity, FEV1(%): forced expiratory volume in one second (%predicted
FEV1), FEV1%(G): percentage of forced expiratory volume in one second.
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disease responsible for PH, including pulmonary artery
hypertension.
Appropriate written informed consent was obtained for publi-
cation of this case report and accompanying images.References
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